



# ***NephroQUEST***

## ***Work Package 4***

***‘Selection and standardisation of indicators for quality of RRT care’***

## ***Deliverable 4.2***

***‘Analysis of potential remaining differences’***

*This deliverable arises from the NephroQUEST project, which has received funding from the European Union, in the framework of the Public Health Programme (projectno: 2006114)*

# *Centre Questionnaire*

## **1. Timing of indicator assessment in relation to interdialytic interval**

- After short interdialytic interval (preferred)
- After long interdialytic interval

## **2. Units and Methods and Timing (in relation to haemodialysis)**

### ***Physical Examination***

#### *Height - units*

- Metres with 2 decimals
- Centimetres

### ***Laboratory measurements***

#### *Blood drawings in haemodialysis patients presented below*

- Are all taken before haemodialysis
- Are all taken after haemodialysis
- Are mostly taken before haemodialysis, but .....is/are taken after haemodialysis
- Are mostly taken after haemodialysis, but .....is/are taken before haemodialysis

#### *Serum Albumin - units*

- g/dL
- g/L
- other, specify .....

#### *Serum Albumin -method*

- BCP
- BCG
- Chromatography
- Nephelometry
- Electrophoresis
- other, specify .....

#### *C-Reactive Protein - units*

- mg/dL
- other, specify .....

#### *C-Reactive Protein -method*

- High sensitivity
- Non high sensitivity

#### *Total cholesterol - units*

- mg/dL
- mmol/L
- other, specify .....

*HDL cholesterol - units*

- mg/dL
- mmol/L
- other, specify .....

*Triglycerides - units*

- mg/dL
- mmol/L
- other, specify .....

*Haemoglobin - units*

- g/dL
- mmol/L
- other, specify .....

*Ferritin - units*

- ng/mL
- µg/L
- other, specify .....

*Serum Iron - units*

- µg/dL
- other, specify .....

*Serum transferrin - units*

- mg/dL
- other, specify .....

*Calcium - units*

- mg/dL
- mmol/
- other, specify .....

*Calcium - method*

- Total
- Corrected
- Ionised

*Phosphorus - units*

- mg/dL
- mmol/L
- other, specify .....

*Parathormone - units*

- pg/mL
- pmol/L

*Parathormone - method*

- Method: .....
- Kit name: .....
- Kit normal range: .....

*Serum urea - units*

- mmol/L
- other, specify .....

*Serum urea - method*

- expressed as urea nitrogen
- expressed as urea

### **3. Therapy characteristics**

***General***

*Type of Erythropoietin Stimulating Agent (ESA) used*

- Epoetin alfa
- Darbepoetin alfa
- Epoetin beta
- Epoetin delta
- CERA
- Biosimilar, specify .....
- Other, specify .....

***PD specific***

*Prescription software for Peritoneal and Renal  $Kt/V_{urea}$  and Peritoneal and Renal  $CCr$*

- Baxter,
- Gambro
- Fresenius
- Other, specify .....

## ***Contributors***

The following NephroQUEST partners and experts contributed to the preparation of this centre questionnaire:

### *Associated partners:*

ERA-EDTA, NBVN, GNFB, CNS, DNS, TÜ, AB, UK, CNR, AMC (WP lead), RENINE, PTN, SCD, KC, TND-TSN and UKRR

### *Collaborating partners:*

Societatea Romana de Nefrologie, Eesti Nefroloogide Selts, Fresenius Medical Care Deutschland, Società Italiana di Nefrologia GmbH, Suomen munuaistautirekisteri (Munuais- ja maksaliitto), Ministry of Health and Welfare, General Hospital of Athens "G.Gennimatas", Nederlandse Federatie voor Nefrologie, Société Suisse de Néphrologie, Hans Mak Instituut and Svensk Njurmedicinsk Förening

*Experts from the QUEST Clinical Working Groups in the areas of Anaemia, Calcium phosphate metabolism, Cardiovascular risk and Dialysis adequacy and the Renal Registry representatives:*

Dr H Holzer, Dr R Kramar and Dr G Mayer (Austria); Dr H Augustijn, Dr C Bovy, Dr F Collart, Dr M Dratwa, Dr M Jadoul, Dr J De Meester, Dr C Tielemans and Dr W Van Biesen (Belgium); Dr F Lopot and Dr I Rychlík (Czech Republic); Dr H Lokkegaard and Dr J Heaf (Denmark); Dr M Luman and Dr M Rosenberg–Ots (Estonia); Dr P Finne, Dr C Grönhagen-Riska, Dr P Groop, Dr E Honkanen, Dr K Metsärinne and Dr H Saha (Finland); Dr G Choukroun, Dr C Couchoud, Dr L Frimat, Dr C Jacquelinet, Dr B Stengel and Dr E Villar (France); Dr C Baldamus and Dr C Wanner (Germany); Dr C Iatrou, Dr G Ioannidis, Dr D Memmos, Dr K Siamopoulos and Dr D Tsakiris (Greece); Dr F Casino, Dr F Conte, Dr L Del Vecchio, Dr A Limido, Dr F Locatelli, Dr F Mallamaci, Dr P Messa, Dr L Pedrini, Dr G Tripepi, Dr E Verrina and Dr C Zoccali (Italy); Dr E Boeschoten, Dr F Dekker, Dr K Jager, Dr J Kooman, Dr K Leunissen, Dr M Noordzij, Dr V Stel and Dr P Terwee (The Netherlands); Dr T Leivestad (Norway); Dr A Debska-Slizien, Dr M Drozd, Dr M Mysliwiec, Dr B Rutkowski and Dr A Wiecek (Poland); Dr A Ferreira, Dr J Frazão, Dr P Neves and Dr M Martins Prata (Portugal); Dr L Gârneata and Dr G Mircescu (Romania); Dr J Arrieta, Dr J Cannata-Andia, Dr A Cases, Dr F Garcia Lopez, Dr J Mauri, Dr F Perez Contreras and Dr O Zurriaga (Spain); Dr J Buturovic Ponikvar (Slovenia); Dr S Schön (Sweden); Dr D Uehlinger and Dr J Wauters (Switzerland); Dr O Özdemir and Dr G Süleymanlar (Turkey); Dr D Ansell, Dr J Harper, Dr E Lamb, Dr A Macleod, Dr K Simpson, Dr J Tattersal, Dr J Tizard and Dr E Will (United Kingdom).